The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it revealed (PDF) that Walmsley took a 16% pay cut in 2024, it also laid out a new compensation ...

Montrose, in partnership with Tanaq Environmental, will provide environmental remediation and planning services at Air Force installations w As one of several firms awarded, Montrose will receive ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of depemokimab in two indications. The proposed ...

Multinational pharmaceutical company GSK’s commitment to invest up to $800 million in its facility near Marietta may have gone elsewhere without tax incentives approved by local officials last year.

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Pfizer (NYSE:PFE) has made significant updates to its diversity, equity, and inclusion (DEI) webpage, becoming the latest Big Pharma after GSK (NYSE:GSK) to revise DEI initiatives amid the Trump ...

One of the most visible corners in Montrose is closer to being transformed into a long-awaited mixed-use high-rise development. After four years of sitting on prime piece of property, real estate ...

A proposal to build a mixed-use tower in Montrose has hit a roadblock after the Houston Planning Commission rejected a variance request needed for the project, sending developers back to the ...

GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from Pfizer.